CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, Avelumab clinical trials

A phase II, open-label, multicenter trial to investigate the clinical activity and safety of Cabozantinib in combination with avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3)

This study looks at new treatments for a specific type of advanced cancer called G3 neuroendocrine neoplasia. It combines two medicines, cabozantinib and avelumab, to see if they can help control the disease and improve patients' health and quality of life.